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The American Psychiatric Association (APA) published a new guideline for Major 
Depressive Disorder (MDD) [1] which will undoubtedly be used by many practitioners to guide 
clinical decision-making. In fact, it is non-psychiatrist clinicians who prescribe the majority of 
antidepressants (AD) [2]. We review the APA’s most recent guideline on MDD and report on 
our observations.  
The Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 
Third Edition is 152 typeset pages in length and the main body is 86 pages. The guideline is 
composed of three sections: Part A, “Treatment Recommendations”; Part B, “Background 
Information and Review of Available Evidence”; and Part C, “Future Research Needs.” Part A is 
the only section that was published in print form and includes the “Executive Summary” [3]. 
This published summary provides recommendation statements and accompanying codes that 
indicate the strength of the recommendation. Part A also includes “Choice of an Initial Treatment 
Modality” (referred to in Table 1 as the “Clarification Section”) and presents additional guidance 
for the implementation of recommendations. Part B, “Background Information and Review of 
Available Evidence,” (referred to in Table 1 as the “Evidence Section”) contains an extensive 
literature review and further explains the recommendation statements. This latter section was not 
published in a medical journal but is available on the publisher’s web site 
(www.psychiatryonline.org). 
This guideline does not contain a decision algorithm or tree or an explicit hierarchy of 
recommendations. Interventions were also not consistently rank-ordered within or between 
sections. In some cases, a careful reading of the complete document results in a statement that 
differed substantially in focus or weight from the recommendation statement in the printed 
summary. For example, drug therapy and psychotherapy are clearly “recommended” as 
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monotherapies in the printed summary. Yet later on in the guideline, it is suggested that that their 
combined treatment “may be used” [1, p. 18], despite the citation research showing the 
superiority of combined treatment in the evidence section. These internal inconsistencies and 
contradictions between sections will likely make it difficult for the clinician to discern exactly 
what course of action is best. Also, especially in the absence of a decision tree, when the 
rationale for a recommendations is vague (e.g., “If a patient with mild depression wishes to try 
exercise alone for several weeks as a first intervention, there is little to argue against it 
[emphasis added]” [1, p. 30], there is not enough evidence to guide clinical decision-making. 
Perhaps most importantly, the guideline does not clearly link, as do many guidelines, the 
levels of recommendation with levels of evidence. As a result, the guideline is not transparent, 
and readers are left to surmise differences within a level of evidence. For example, it is unclear 
when and why AD medication should be the frontline treatment. Additionally, the risk/benefit 
issue when recommending AD medication as a first line treatment for individuals with mild 
depression is not adequately addressed. Although recent meta-analyses questioning the efficacy 
of ADs are cited in the guideline [4, 5], the context in which they are referenced does not convey 
the primary conclusions drawn by both meta-analyses: AD medication should not be the default 
recommendation for mild to moderate depression. Instead, the following statement is made in the 
guideline’s executive summary: “Response rates in clinical trials typically range from 50-75% of 
patients, with some evidence suggesting greater efficacy relative to placebo in individuals with 
severe depressive symptoms as compared to those with mild to moderate symptoms” [1, p. 31]. 
Thus, the reader is left with the erroneous impression [6, 7] that there is a clear evidence base for 
generally recommending the use of ADs as the initial treatment for mild to moderate depression, 
and ADs work even more effectively for severe depression. This lack of clarity and the 
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recommendation of antidepressants as a first-line choice for mild depression stand in contrast to 
guidelines produced by non-specialty organizations such as the National Institute for Clinical 
Excellence (NICE), which addresses the risk/benefit issue and explicitly states that 
antidepressant medication should not be a first line choice for individuals with mild depression 
[8]. 
Given the length of this CPG it is likely that a typical reader—a busy clinician—will 
focus reading on the Executive Summary, which by itself does not provide sufficient guidance or 
acknowledge existing uncertainty and controversy in the field. On the other hand, a clinician 
seeking to understand the Executive Summary by reference to the text will find differing 
recommendations in the various sections. Indeed, like the parable of the blind men and the 
elephant, readers of this guideline will receive different guidance based on what part they read.  
It is also noteworthy that in the case of this CPG, every APA work group member 
reported commercial ties to the companies that manufacture the medications recommended in the 
guideline, and the majority (4/6), including the chair, serve on speakers bureaus or advisory 
boards [1, pp. 2-3]. Financial conflicts of interest have been a problem for many CPGs,  and the 
APA attempted to mitigate any biasing effect by adding a review panel that would evaluate the 
guidelines for possible industry influence (they concluded there was none). Given the primacy of 
pharmacotherapy, specifically newer, branded medications, these financial associations raise 
questions about the objectivity and integrity of the guideline because they give the appearance of 
undue industry influence. In fact, the IOM’s most recent report states clearly that individuals 
with financial relationships with industry should be prohibited from participating on guideline 
development committees [9]. 
5 
 
The APA leadership noted that the goal of these guidelines was to provide a “full range 
of treatment options” [10]. This is a laudable and important goal and certainly many patients 
benefit from pharmacotherapy. However, we believe that the usefulness of this practice guideline 
could be enhanced by linking levels of recommendations with levels of evidence; by including a 
decision tree or algorithm; and by addressing more fully the controversies that exist regarding the 
risk, benefits, and alternatives to psychotropic medications. Additionally, and in keeping with 
recent guideline development standards such as those identified in the IOM report, future 
guidelines produced by the APA should be authored by a multidisciplinary team of experts who 
do not have industry ties [see also, 11].     
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Table 1. Examples of Inconsistencies among Sections and Implications for Treatment.  
 
